Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz's Somatropin Becomes First Biosimilar Approved In Japan

This article was originally published in The Pink Sheet Daily

Executive Summary

Japan's Ministry of Health, Labor and Welfare approved the recombinant human growth hormone injection less than a year after releasing draft guidelines and three months after Sandoz/Novartis submitted the application.
Advertisement

Related Content

Korea FDA Gears Up To Release Biosimilar Guidelines Modeled After EU Rules
Korean LG Life Sciences Plans BLA Submission For Biosimilar Somatropin To U.S. FDA
Japan Chemical Research, Kissei Submit First Biosimilar Application In Japan
Malaysia Releases Regulatory Guidance On Biosimilars, But Local Manufacturers Not Ready To Produce - Analyst
PhRMA Urges Japan To Create Separate Regulations For Biosimilars
Japan Posts Draft Guidance On Biosimilars; Seeks Public Comment
Japan Posts Draft Guidance On Biosimilars; Seeks Public Comment

Topics

Advertisement
UsernamePublicRestriction

Register

PS069622

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel